Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study-Reference-Cited by-同舟云学术

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

Published:2018-06-04 Issue:1 Volume:38 Page:32
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Kim Jung Hoon¹,Lee Sang-Cheol²,Oh Sung Yong³,Song Seo-Young⁴,Lee Namsu⁵,Nam Eun Mi⁶,Lee Soonil⁷,Hwang In Gyu⁸,Lee Hyo Rak⁹,Lee Kyu Taek²,Bae Sang-Byung²,Kim Han Jo²,Jang Joung Soon⁸,Lim Do Hyoung⁷,Lee Hyun Woo¹⁰,Kang Seok Yun¹⁰,Kang Jung Hun¹

Affiliation:

1. Department of Internal Medicine, Institute of Health Sciences; Gyeongsang National University; 15 Jinju-daero 816 beon-gil Jinju 52727 Republic of Korea

2. Divsion of Hematology and Oncology, Department of Internal Medicine; Soonchunhyang University Hospital Cheonan; Cheonan 31151 Republic of Korea

3. Department of Internal Medicine; Dong-A University Hospital; Busan 49201 Republic of Korea

4. Department of Internal Medicine; Kangwon National University School of Medicine; Chuncheon 24289 Republic of Korea

5. Divsion of Hematology and Oncology, Department of Internal Medicine; Soonchunhyang University Hospital Seoul; Seoul 04401 Republic of Korea

6. Department of Internal Medicine; Ewha Womans University, College of Medicine; Seoul 07985 Republic of Korea

7. Department of Internal Medicine; Dankook University Hospital; Cheonan 31116 Republic of Korea

8. Department of Internal Medicine; Chung-Ang University, College of Medicine; Seoul 06973 Republic of Korea

9. Division of Hematology and Medical Oncology, Department of Internal Medicine; Korea Cancer Hospital; Seoul 01812 Republic of Korea

10. Department of Hematology-Oncology; Ajou University Hospital; Suwon 16499 Republic of Korea

Funder

Hanmi Pharmaceutical Co. Ltd.

Soonchunhyang University Research fund

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-018-0304-1.pdf

Reference26 articles.

1. Estimation of cancer deaths in Korea for the upcoming years;Bae;J Korean Med Sci.,2002

2. The economic burden of cancer in Korea in 2002;Kim;Eur J Cancer Care (Engl),2008

3. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007;Jung;J Korean Med Sci.,2010

4. Detecting early pancreatic cancer: problems and prospects;Chari;Semin Oncol.,2007

5. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors;Conlon;Ann Surg.,1996

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic therapy for metastatic pancreatic cancer;Malignant tumours;2023-10-09

2. Analysis of the cost‐effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan;Cancer Medicine;2023-10

3. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review;Cancer Treatment Reviews;2023-02

4. Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study;Drugs in R&D;2022-08-20

5. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer;International Journal of Clinical Oncology;2022-05-30